article thumbnail

The morality (and patentability) of inventions derived by immoral means (T 2510/18)

The IPKat

Cases relating to the exclusion of patentable subject matter on moral grounds are rare, and always serve to highlight the underlying moral and political framework necessary for a well-functioning IP system. The recent case T 2510/18 considered whether an invention derived from traditional remedies by dishonest means was immoral.

Invention 113
article thumbnail

All the IP News that Mattered in 2024

IP Watchdog

The past year has included some monumental developments in the world of IP - and adjacent to IP - that will affect law and practice for years to come.

IP 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI, Invention Harvesting and the Patent Backlog | IPWatchdog Unleashed

IP Watchdog

This week on IPWatchdog Unleashed I speak with my friend Jason Harrier, former Chief Patent Counsel at Capital One and current co-founder and General Counsel of artificial intelligence (AI) company IP Copilot.

article thumbnail

Dragons' Den IP Blog - Series 22 Episode 3

Dragons' Den

UK businesses who find themselves all at sea when expanding into a new territory are able to access support from the IPOs network of international IP Attachs IP experts based across the world in Europe, China, Latin America, North America, Southeast Asia, Gulf States and India.

article thumbnail

AI IP Year in Review - Five Key Takeaways from the 2024 House Judiciary Hearing on AI-Assisted Inventions and Creative Works

JD Supra Law

Over the past two years, the Senate and House have held public hearings to address how, if at all, AI should be regulated and to what extent IP rights should inhere in AI-assisted inventions and creative works. Most recently, in April 2024, the House Judiciary Subcommittee on Courts, Intellectual Property, and the Internet.

article thumbnail

Beyond the process: Securing robust IP protection for cell therapies

The IPKat

However, unlike traditional pharmaceuticals, these "living medicines" present unique IP challenges that can make or break a biotech's future. However, manufacturing IP has many intrinsic pitfalls, and is often not considered by investors to provide adequate exclusivity and surety of return of investment.

IP 64
article thumbnail

The benefits and pitfalls of drug manufacturing IP (T 2543/22)

The IPKat

The case highlights some interesting aspects of pharma IP strategy, particularly as related to manufacturing IP and whether this is best protected with patents or trade secrets. In these circumstances, manufacturing IP is another way of protecting return of investment in the drug.

IP 64